Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Hes family bHLH transcription factor 4 (HES4)
- Target
- HES4
- Molecular classification
- Transcription factor, Basic helix-loop-helix (bHLH) family, Transcriptional repressor
01
Overview
Hes family bHLH transcription factor 4 (HES4) is a human transcriptional repressor belonging to the basic helix-loop-helix (bHLH) protein family. It regulates gene expression by binding to specific N-box DNA motifs (5'-CACNAG-3') and is crucial in several developmental processes. HES4 is important for T-cell lineage specification via the Notch1 signaling pathway, is involved in patterning of tissue boundaries, and promotes bone (osteogenic) differentiation while inhibiting adipogenic differentiation. Unlike other Hes family proteins, HES4 does not strictly inhibit B-cell lineage specification but supports the progression of early T-cell development. HES4 overexpression has been linked to poor prognosis and increased invasiveness in osteosarcoma, suggesting a potential oncogenic role. Despite significant biological functions in development and disease, HES4 itself is not a direct therapeutic target, nor are there currently known drugs or modulators directed at this molecule
- Other names
- Transcription factor HES-4BHLHB42hHES4bHLHb42Class B basic helix-loop-helix protein 42Hairy and enhancer of split 4bHLH factor Hes4
02
Mechanism of action
Not applicable; no drugs targeting HES4 are described
03
Biological functions
Regulation of transcription by RNA polymerase IIT-cell development (Notch1 signaling pathway participation)Osteogenesis and bone differentiationPatterning of tissue boundariesPromotion of floor plate and prechordal plate developmentRegulation of lineage commitment in bone marrow stromal cells (BMSC)Inhibition of adipogenesis
04
Disease associations
Cancer (notably osteosarcoma; HES4 overexpression associated with aggressive tumor behavior and poor prognosis)Possible oncogenic roleTrichuriasis (reported association)Lateral sinus thrombosis (reported association)
05
Safety considerations
None specifically reported related to HES4 as a therapeutic target, since it is not currently a druggable target or therapy focus
06
Biomarkers
HES4 expression is explored as a potential prognostic biomarker in osteosarcoma due to its association with aggressive, metastatic tumor behavior and poor patient prognosis
Beyond the preview
Go deeper on Hes family bHLH transcription factor 4 (HES4).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Hes family bHLH transcription factor 4 (HES4).